Celsius Holdings news

Celsius received a Zacks Rank #5 (Strong Sell) rating due to downward earnings estimate revisions (-3.1% over 30 days for current quarter), recent earnings misses (-14.29% EPS surprise), stock underperformance (-11% vs S&P 500 +1%), and premium valuation (Grade D). While revenue growth is expected at 26.6% for current fiscal year, the company's near-term outlook appears challenged.

The company is the defendant in a securities fraud class action lawsuit alleging material misstatements and omissions regarding health risks of its Alani Nu products, improper marketing to minors, and failure to adequately disclose cardiac risks. These allegations represent significant legal, reputational, and financial risks to the company.

The company faces a securities class action lawsuit alleging material misrepresentation regarding product safety and marketing practices to minors. A teenager's death linked to the product and a state attorney general investigation triggered significant stock price declines (4.18% and 7.53% on separate dates), indicating serious legal and reputational risks.

The stock underperformed the broader market with a 1.13% daily decline and 12.91% monthly loss. The company received a Zacks Rank #5 (Strong Sell) rating with recent downward EPS estimate revisions. Despite revenue growth expectations, quarterly EPS is forecasted to decline 16.67% year-over-year, and the stock trades at a premium valuation (Forward P/E of 19.6 vs. industry average of 14.06), indicating overvaluation concerns.

CEO made modest $500k share purchase, but no business performance data or context provided to evaluate company fundamentals or justify the investment thesis beyond insider buying activity.

Despite a single-day outperformance, CELH carries a Zacks Rank #5 (Strong Sell) rating. The stock has declined 7.47% over the past month, EPS is forecasted to decline 16.67% year-over-year, and the company trades at a premium valuation (Forward P/E of 18.35 vs. industry average of 14.15). Recent analyst estimate revisions have been slightly downward, indicating weakening confidence in near-term performance.

The company faces a class action lawsuit alleging material misrepresentations regarding product safety, inadequate warnings about cardiac risks, and undisclosed marketing to minors. These allegations suggest potential regulatory violations, reputational damage, and financial liability, all of which negatively impact investor confidence and shareholder value.

Despite bullish Wall Street analyst ratings (ABR 1.59 with 72.7% Strong Buy), the Zacks Rank assigns a Strong Sell (#5) rating based on declining earnings estimate revisions (down 7.5% to $1.47). The article emphasizes that earnings estimate revisions are more reliable predictors of near-term stock performance than analyst recommendations, indicating legitimate concerns about the company's earnings prospects and potential near-term stock decline.

Demonstrates impressive 85% revenue growth and expanding market share, but carries significant risks including heavy reliance on PepsiCo (43% of revenue), low 4% net margin, high P/E ratio of 117.69, and uncertainty around long-term consumer beverage preferences. Growth is attractive but execution risk is elevated.

Company missed Q2 earnings estimates, reported declining flagship brand sales (-12% YoY), and faces intense competition. Stock has fallen 75% from peak, and analyst expresses concerns about growth durability despite seemingly attractive valuation.

Stock down 36% in 2026 with flagship brand losing momentum despite portfolio expansion. Represents a high-risk, single-category bet dependent on successful brand integration and turnaround execution.

Positioned as a growth competitor in the expanding energy drink segment with potential to gain market share against established players. The article suggests it as a viable investment alternative.

Company faces securities fraud investigation and regulatory scrutiny from Texas Attorney General regarding deceptive marketing practices of high-caffeine products to children and teens. Stock declined 7.53% on investigation announcement, indicating significant investor concern about legal and reputational risks.

Stock is trading at attractive valuations (14x forward earnings vs. historical 100x+), Alani Nu acquisition is performing exceptionally well with 60% YoY growth, company controls 20%+ of U.S. energy drink market, profit margins expanding significantly, and international expansion showing strong results.

The article presents a balanced view of Celsius as a potential investment opportunity. While sales are soaring and the stock is down 50% from highs (suggesting potential value), the emergence of a new Costco offering poses competitive concerns. The title frames it as an undervaluation question rather than a clear recommendation.

While Celsius shows solid growth metrics (20% revenue growth, 55% EPS growth through 2028) and successful product innovation with the Alani Nu acquisition, the author expresses concerns about intensifying competition and views it as a riskier investment compared to Dutch Bros. The stock's extreme volatility and past peak decline also suggest caution.

While Celsius has strong fundamentals with 19.8% market share and growing consumer interest in health-focused drinks, the stock faces significant headwinds from intense competition, low barriers to entry, and likely valuation contraction. The investment is characterized as high-risk with uncertain outcomes despite growth potential.

Stock is dropping significantly (down 4.64% on the day mentioned, and 49% from its 52-week high according to related articles). Competition from Costco has spooked investors, indicating near-term negative pressure on the stock price.

Despite recent 21% decline, the article argues the pullback is overdone. Celsius shows strong fundamentals: 85-173% revenue growth post-Alani Nu acquisition, consistent earnings beats, reasonable 16x forward P/E multiple, and competitive advantages over Costco's entry (weight-loss benefits, wider distribution). Analysts from Roth Capital, Citi, and TD Cowen support the bullish case.

Stock has fallen 49% from 52-week high; facing intense competition from Costco's cheaper alternative; gross margins declining; valuation still appears expensive relative to competitive risks despite recent sell-off; analyst recommends staying on sidelines

Stock slumped 17.86% this week with no specific positive catalysts mentioned

The company achieved record $2.5 billion revenue with 117% year-over-year Q4 growth driven by the Alani Nu acquisition. The acquisition successfully captured a new wellness-focused demographic and established a high-margin growth platform for 2026, offsetting core brand growth slowdown.

Strong revenue growth (117%), significant EPS growth (86%), successful Alani Nu integration driving 136% pro forma revenue growth, Bank of America double upgrade to 'buy', expected shelf space gains and margin improvements in 2026, and stock has more than doubled over the past year.

Mentioned as a competitor to Monster Beverage in the energy drink market but no detailed analysis provided.

Positioned as a beneficiary of PepsiCo's 11% stake and strong growth in energy drink market (8% annual spending growth), with increasing consumption among key demographics (25-44 age groups) and resilience against GLP-1 drug trends.

CEO John Fieldly made a $500k share purchase, indicating executive confidence in the company's prospects.

Stock down 46% from highs but trading at reasonable 24x forward P/E for a top-tier brand in fast-growing energy drink category. Company holds ~20% U.S. energy drink market share, reported 11% YoY revenue growth with stronger 31% retail sales growth, and has significant international expansion runway (currently small portion of revenue with 15% target). PepsiCo partnership strengthens distribution capabilities and portfolio diversification through brands like Alani Nu and Rockstar Energy supports growth.

Mentioned as a competitive peer in the energy drink market with a lower forward P/E ratio of 22.6, suggesting more attractive valuation, but no specific performance data or recommendation provided in the article.

Presented as a successful example of a micro-cap stock that attracted consumer attention before institutional investors noticed it, validating Lynch's strategy of observing consumer trends.

Mentioned as one of the five undervalued stocks identified in the article; The Motley Fool recommends it

Mentioned as a beneficiary of PepsiCo's distribution partnership for its Alani Nu drink line, which contributed to PepsiCo's 7% beverage revenue growth in North America. The partnership highlights Celsius's growing market appeal in the healthier beverage segment.

Most direct bet on functional energy drinks with strong brand positioning among health-conscious younger consumers. PepsiCo partnership provides major distribution advantage. Stock down 28% in 2026 but trades 90% below consensus price target of $60.90, offering value for volatility-tolerant investors.

Celsius is mentioned only as context for Gerry David's previous accomplishments. The article does not contain any new information or developments regarding Celsius itself, making the sentiment neutral from a news perspective.

Listed as a top holding of Divisadero Street Capital Management ($89.95 million, 4.2% of AUM) but no specific news or analysis provided about the company itself.

Up 7.43% as part of broader market gains in consumer discretionary sector

Strong 86% full-year sales growth and 117% Q4 growth, deepened partnership with PepsiCo providing distribution advantages, strategic positioning as PepsiCo's energy lead, and early-stage international expansion with significant growth potential ahead.

Listed as MIG Capital's fifth-largest holding at $33.93M (5.8% of AUM). No specific news or analysis provided about the company itself in this article.

While the company has achieved impressive historical growth and strategic acquisitions, the author cites expensive valuation (28.4x forward P/E), slowing growth prospects (10% CAGR expected 2026-2028), intense competition from larger rivals (Red Bull 35.9%, Monster 27.3% vs Celsius 19.8% market share), lack of durable competitive moat, and stagnating retail sales in H2 2025 as reasons to avoid the stock.

Reported record full-year 2025 revenue of $2.5 billion (86% increase), achieved ~20% dollar share of U.S. energy drink category in Q4 2025, and generated adjusted EBITDA of $619.6 million (142% YoY growth). Strong portfolio integration and market leadership position.